

Research Article

Prediction of Acute Inhalation Toxicity Using *in vitro* Lung Surfactant Inhibition

Jorid B. Sørli^{1,*}, Yishi Huang^{1,*}, Emilie Da Silva¹, Jitka S. Hansen^{1,2}, Yi Y. Zuo³, Marie Frederiksen¹, Asger W. Nørgaard¹, Niels E. Ebbelhøj^{4,5}, Søren T. Larsen¹ and Karin S. Hougaard¹

¹The National Research Centre for the Working Environment, Copenhagen, Denmark; ²University Library of Southern Denmark, Odense, Denmark; ³Department of Mechanical Engineering, University of Hawaii at Manoa, Honolulu, HI, USA; ⁴The Danish Poison Information Centre, Bispebjerg University Hospital, Copenhagen, Denmark; ⁵Department of Occupational and Environmental Medicine, Copenhagen, Denmark

Summary

Private consumers and professionals may experience acute inhalation toxicity after inhaling aerosolized impregnation products. The distinction between toxic and non-toxic products is difficult to make for producers and product users alike, as there is no clearly described relationship between the chemical composition of the products and induction of toxicity. The currently accepted method for determination of acute inhalation toxicity is based on experiments on animals; it is time-consuming, expensive and causes stress for the animals. Impregnation products are present on the market in large numbers and amounts and exhibit great variety. Therefore, an alternative method to screen for acute inhalation toxicity is needed. The aim of our study was to determine if inhibition of lung surfactant by impregnation products *in vitro* could accurately predict toxicity *in vivo* in mice. We tested 21 impregnation products using the constant flow through set-up of the constrained drop surfactometer to determine if they inhibited LS function or not. The same products were tested in a mouse inhalation bioassay to determine their toxicity *in vivo*. The sensitivity was 100%, i.e. the *in vitro* method predicted all the products that were toxic for mice to inhale. The specificity of the *in vitro* test was 63%, i.e. the *in vitro* method found three false positive of the 21 tested products. Six of the products have been involved in accidental human inhalation where they caused acute inhalation toxicity. All of these six products inhibited lung surfactant function *in vitro* and were toxic to mice.

Keywords: Impregnation product, lung surfactant, constrained drop surfactometer, acute inhalation toxicity, OECD TG 403 and 436

1 Introduction

Toxicity testing is traditionally performed in experimental animals for determination of toxic and non-toxic exposure levels. However, this practice is out of pace with current legislative and ethical developments. Much of the criticism is centered on the most common parameter used by authorities, the lethal concentration, 50% (LC₅₀), i.e., the concentration in inhaled air that is lethal to 50% of the animals. The LC₅₀ uses death as the endpoint, an outcome that is associated with substantial suffering. Based on this rationale, it is no longer permitted to test for the LC₅₀ in Denmark (BEK no. 12 of 07/01/2016). The practice is also strongly discouraged in the rest of the EU according to Directive 2010/63/EU (EU, 2010) due to changes towards stricter regulations of experimental animal use. The bioassay used for testing of acute inhalation toxicity in the current study uses signs of potentially lethal lung damage observed during the experiment as an endpoint, rather than the death of the animal. Furthermore, acute toxicity caused by substance inhalation can have a very steep concentration-response curve, not least for the focus substances of this paper: impregnation products (IPs).

The development of alternative methods for testing of chemical toxicity has come a long way, but no alternative methods exist for assessment of acute inhalation toxicity at present (Zuang et al., 2015). Any substance that reaches the deepest parts of the lungs can potentially cause acute inhalation toxicity, but the underlying mechanism is poorly understood and may vary depending on the characteristics of the substance. We have investigated the hypothesis that lung surfactant (LS) is a prime target in acute inhalation toxicity. LS covers the deepest parts of the lungs, the respiratory bronchioles and the alveoli, as a thin liquid film and is continuously formed and secreted by the alveolar type II cells (Zuo et al., 2008). LS has several functions in the lungs, but the most important is to lower the surface tension at the air-liquid interface during respiration (Zuo et al., 2008). During breathing, the lungs are continuously exposed to the surrounding environment via the inhaled air, and the LS film is the first barrier that meets any inhaled substance. This

*authors contributed equally
Received May 18, 2017;
Accepted August 14, 2017;
Epub August 17, 2017;
doi:10.14573/altex.1705181



This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International license (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited.

interaction between substance and surfactant usually has little or no consequences for LS function, but some inhaled chemicals can disrupt the function of LS. This may lead to an increase in alveolar surface tension and subsequently alveolar collapse (Enhörning, 2001). Reopening of an atelectatic area requires energy, and breathing becomes labored. The friction (caused by the opening of the collapsed areas) may also cause damage to the airway epithelium, allowing extravasation of blood and serum proteins into the lung lumen. These proteins inhibit LS function further (Ishizaka et al., 2004).

IPs frequently cause acute inhalation toxicity in humans after accidental inhalation following application of the product. Instances where people have been injured after inhaling aerosolized products are most often found as case reports in the literature (Fagan et al., 1977; Muller-Esch et al., 1982; Schicht et al., 1982; Okonek et al., 1983; Thibaut et al., 1983; Woo et al., 1983; Christensen et al., 1984; CDC, 1993a,b; Kelly and Ruffing, 1993; Laliberte et al., 1995; Yamashita and Tanaka, 1995; Burkhart et al., 1996; Testud et al., 1998; Jacobsen et al., 1999; Ota et al., 2000; Bonte et al., 2003; Malik and Chappell, 2003; de Groot et al., 2004; Heinzer et al., 2004; Lazor-Blanchet et al., 2004; Tizzard and Edwards, 2004; Wallace and Brown, 2005; CDC, 2006; Vernez et al., 2006; Ebbenhøj and Bang, 2008; Daubert et al., 2009; Hashimoto et al., 2009; Khalid et al., 2009; Epping et al., 2011; Fukui et al., 2011; Weibrecht and Rhyee, 2011; Duch et al., 2014; Nakazawa et al., 2014; Kikuchi et al., 2015; Bennett et al., 2015). These reports involve several different IPs and describe outbreaks involving from one to hundreds of people. The symptoms are similar for the different IPs; they develop quickly, in minutes to hours after exposure. The pulmonary symptoms include shortness of breath, coughing and tightness in the chest, but may also include systemic indicators such as headache, vomiting or fever. The symptoms usually spontaneously resolve within days of exposure, but may in some cases continue for an extended period of time (months after the inhalation incident) (Schicht et al., 1982; Burkhart et al., 1996; Ota et al., 2000; Wallace and Brown, 2005; Khalid et al., 2009; Fukui et al., 2011; Kikuchi et al., 2015).

The present study aimed to investigate if disruption of LS function *in vitro* can be used as an alternative method to test for acute inhalation toxicity caused by IPs. An alternative method will firstly reduce the need for experimental animal testing by identifying potentially toxic products *in vitro*, allowing for removal of toxic products before undertaking *in vivo studies*. Secondly, testing impregnation products *in vitro* will lead to better consumer safety by easing identification of potentially hazardous products before human health is jeopardized.

As the alternative method, we use the constant flow through set-up of the constrained drop surfactometer (cf-CDS) (Valle et al., 2015; Sørli et al., 2015a) as a screening tool to assess the effect of IPs on LS function. The cf-CDS method is a novel *in vitro* method that mimics the conditions for the LS in the lungs (Sørli et al., 2015a). A surfactant drop is placed on a hollow pedestal with a sharp edge, the volume (and so the surface area) is adjusted by introducing and removing liquid through the base of the pedestal by a syringe connected to a computer controlled stepping motor. This simulates the movement of the LS layer during breathing. Images of the drop are collected as it is cycled between the set minimum and maximum volume, and based on these images a computer program, ADSA (axisymmetric drop shape analysis) (Zuo et al., 2004; Saad and Neumann, 2016) calculates the surface tension of the drop continuously. To determine if the cf-CDS method can predict if IPs are toxic to inhale, we exposed mice to the same IPs by inhalation, while continuously monitoring their respiration pattern to determine the effect on lung function *in vivo*.

The mouse model used in the present study has previously been used to assess the airway irritation potential of industrial chemicals (Alarie, 1973; Nielsen et al., 2005). The effect of the test substance is assessed based on changes in the breathing pattern during respiration (Alarie, 1973). Inhalation of some aerosolized IPs leads to an irreversible reduction in tidal volume (Nørgaard et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b). This effect has been proposed to be driven by interaction between the IP and the LS, which may lead to development of atelectasis (Nørgaard et al., 2010). Atelectasis may progress to tissue damage and edema, and product testing may therefore cause irreversible and lethal lung damage (Hubbs et al., 1997; Pauluhn et al., 2008; Nørgaard et al., 2010). We refined the mouse model during the course of the experiments to keep the potential suffering of the animals at the lowest possible level. The refinements are described under the section "Refinement of the *in vivo* model".

Our aim was to determine if LS inhibition could be used as an alternative method for testing acute inhalation toxicity of IPs. In the long run, this method may prove to be an alternative to the currently regulatory accepted OECD guidelines OECD TG 403 and 436 for acute inhalation toxicity using animals (OECD, 2009a, b). 21 IPs were tested in the cf-CDS method, whereof 6 have been involved in human inhalation accidents. As 10 of the products had been previously been tested for acute inhalation toxicity in mice, the additional 11 products were tested in the *in vivo* bioassay in the present study. The results from the *in vitro* method were subsequently compared to the *in vivo* toxicity in both mice and humans.

2 Animals, materials and methods

Generation of IP aerosols

Aerosols of the tested IPs were generated in the same way for *in vitro* and *in vivo* experiments. The product was led from a glass syringe into a Pitt no. 1 jet nebulizer (Wong and Alarie, 1982) by an infusion pump (New England Medical Instruments Inc., Medway, MA, US). In the *in vitro* experiments, the exposure air-stream was led through glass columns and into the 1.9 l chamber of the cf-CDS and sucked out through the baseplate. For the *in vivo* mouse bioassay, the IP aerosols entered a 20 l exposure chamber of glass and stainless steel (Clausen et al., 2003), with an air exchange rate of approximately 1 min⁻¹. Outlet air was passed through a series of particle- and active coal-filters before exhaust to the atmosphere.

In vitro method measuring LS inhibition

LS inhibition *in vitro* was tested using the cf-CDS method (Sørli et al., 2015a), by exposing a drop of LS to increasing amounts of IP. A drop of LS (Curosurf®, 10 µl of 2.5 mg/ml) was placed on a hollow based pedestal with a sharp edge, and subjected to dynamic cycling at 40 cycles/min and less than 30% compression. The cf-CDS and aerosol generation setup was kept at 37°C inside a heating box. In short, a steady stream of air (containing the aerosolized IP) flowed from the top to bottom of the chamber, to expose the LS to

an increasing concentration of the tested product. The exposure concentration was monitored by a quartz crystal microbalance (QCM) placed close to the pedestal.

The LS was cycled prior to exposure to obtain a baseline value for the surface tension, and any experiment with a minimum surface tension of >5 mN/m was discarded. The cycling of the LS was stopped at intervals and the drop refilled with buffer, to replace liquid that had evaporated. Images were continuously taken of the drop and analyzed by ADSA. The primary output was the surface tension of the LS drop. If the IP inhibited the LS (as described below), the aerosolization rate was reduced. Thus, IPs were tested with the lowest aerosolization rate that caused inhibition within 5 min. All non-inhibiting IPs were tested for 10 min at the highest possible aerosolization rate. After each experiment, the exposure was stopped and the chamber was left for 5 to 10 min to allow the volatile fraction of the IP to evaporate from the QCM and the deposited material to reach a stable plateau.

A surface tension plot, where each dot corresponded to a single captured drop image, was created by ADSA.

Representative surface tension profiles of LS subjected to inhibitory and non-inhibitory IPs can be found in Figure S1 (supplementary file at doi:10.14573/altex.1705181s). Inhibition of LS activity was defined as at least seven consecutive minimum surface tensions of ≥ 10 mN/m during compression. At this minimum surface tension, atelectasis is thought to occur *in vivo* (Tashiro et al., 1998). Inhibition of LS function could, alternatively, be defined by an IP film forming on the drop (see below, Fig. 1).

Most of the inhibitory IPs inhibited the LS function by preventing the cycling LS from reaching a minimum surface tension below 10 mN/m. However, some products inhibited the LS function by forming a thick film on the surface of the surfactant droplet during dynamic cycling. The IP film held together the droplet and increased the surface viscosity, thus resulting in the top of the droplet being “flattened” during compression (Fig. 1). The thickness of the IP film seemed to gradually increase with time. For the products “Stain repellent nano” and “Liquid stain protection”, the LS was inhibited as a low surface tension could not be reached (the minimum surface tension increased to >10 mN/m after 9 and 30 sec of exposure, respectively). In addition, a film appeared 3 or 10 minutes after the start of exposure, respectively. For “HG textile” and “HG leather” the minimum surface tension did not increase to levels above 10 mN/m, however a film formed on the LS drop after less than 2 min of exposure. The “flattened” images are analyzed as having a low surface tension by ADSA, but with continuous cycling the IP film distorted the axisymmetry of the drop by wrinkling the surface or skewing the drop. The latter images cannot be analyzed by ADSA and it gives a warning. The warning, combined with visual confirmation of the “flattening” of the drop defined the products as inhibitory to LS. If the IP film “only” flattened the drop the determination had to be done visually, however the drop image is followed visually throughout the experiment, and the flattening is very noticeable.




Fig. 1: Images of the surfactant drop with IP film formation during compression

A LS drop not exposed to IP (left) has a rounded shape, when a IP film forms on the surfactant drop the top is “flattened”. LS drop exposed to “Liquid stain protection” (middle) and “Stain repellent nano” (right). The irregularities seen on the top stems from the film being wrinkled during compression.

Animals

The mouse bioassay data for 10 of the IPs have been published previously (see Tab. 1). For the 11 additional IP bioassays, mice were of a similar strain (BALB/cJ, as the BALB/cA strain is no longer available) and age as in previous experiments and were housed under the same conditions. The mice were kept behind a specific pathogen free (SPF) barrier. Thus, a further 212 inbred BALB/cJ male mice aged 5-8 weeks at arrival were purchased from Taconic M&B (Ry, Denmark) and housed in polypropylene cages (1290D Eurostandard type III from Scanbur, 425 x 266 x 155mm) furnished with aspen bedding material (Tapvei, Estonia), enriched with a mouse house (80-ACRE011, Techniplast, Italy) and small aspen blocks (Tapvei, Estonia). The mice were 6-12 weeks old when they were used in the bioassay. The photo-period was from 06:00 to 18:00, the temperature 21°C and relative humidity 55%. Cages were sanitized twice weekly. Food (Altromin no. 1324, Altromin, Lage, Germany) and municipal tap water were available ad libitum. The mice were randomly assigned to cages upon arrival, 3-4 mice per cage, and acclimatized for a minimum of one week. Generally, mice from the same cage were used in the same experiment, the mice had not been used for any other procedures prior to the bioassay. The experiments were performed between 09:00 and 15:00. The breathing pattern of each mouse was monitored in real time, in addition the mice were visually monitored throughout the experiment.

Ethical statement

Treatment of the animals followed procedures approved by The Animal Experiment Inspectorate, Denmark (Permissions No. 2006/561-1123-C3, 2012-15-2934-00616-C1 and 2014-15-2934-01042-C2). All experiments were performed by trained personnel and conformed to the Danish Regulations on Animal Experiments (LBK nr. 474 af 15/05/2014 and BEK nr 1589 af 11/12/2015), which include guidelines on care and use of animals in research. Anesthesia was not used during the experiments, because the bioassay depends on the animals being fully awake with uncompromised breathing. The acute inhalation toxicity was observed as a

rapid depression of the tidal volume. The mouse bioassay has gone through several rounds of refinement as described below. The exact number of animals used to test the toxicity of each product is given in Table S1 (doi:10.14573/altex.1705181s).

Tab. 1: Source of the 21 impregnation products used in this study, and references to previously published *in vivo* mouse bioassay data and known human toxicity

Impregnation product	Source	<i>In vivo</i> data published	Human toxicity
"Wood impregnation"	Dr Scheepers, Radboud University Nijmegen (The Netherlands)	Yes, (Sørli et al., 2015b)	Yes, "Human toxicity" and (Scheepers et al., 2016)
"Stain repellent super"	Akemi GmbH (Nürnberg, Germany)	Yes, (Duch et al., 2014)	Yes, "Human toxicity" and (Duch et al., 2014)
"Liquid stain protection"	Dorothee Walter, Fraunhofer ITEM, Germany		Yes, "Human toxicity" and (Hahn et al., 2015)
"Faceal oleo MG"	PSS Interservice (Geroldswil, Switzerland)		Yes, see "Human toxicity"
"HG textile" *	HG International (Almere, The Netherlands)		Yes, see "Human toxicity"
"HG leather" *	HG International (Almere, The Netherlands)		Yes, see "Human toxicity"
"Antismuds"	ENC Natursten A/S (Svendborg, Denmark)		
"Footwear protector"	Granger's (Derbyshire, UK)	Yes, (Sørli et al., 2015b)	
"Nakano impregnation"	Harald Nyborg (Odense, Denmark)		
"Non-absorbing floor materials"	NanoCover (Aalborg, Denmark)	Yes, (Nørgaard et al., 2010)	
"Rim sealer"	NanoLotus (Odense, Denmark)	Yes, (Sørli et al., 2015b)	
"Stain repellent nano"	Akemi GmbH (Nürnberg, Germany)		
"Stain repellent"	Akemi GmbH (Nürnberg, Germany)		
"Bath and tiles"	NanoCover (Aalborg, Denmark)	Yes, (Nørgaard et al., 2010)	
"Faceal oleo HD"	PSS Interservice (Geroldswil, Switzerland)		
"Special textile coating"	NanoLotus (Odense, Denmark)	Yes, (Nørgaard et al., 2014)	
"Textiles and leather concentrate"	NanoCover (Aalborg, Denmark)	Yes, (Nørgaard et al., 2014)	
"Textiles and leather"	NanoCover (Aalborg, Denmark)	Yes, (Sørli et al., 2015b)	
"Car glass"	NanoCover (Aalborg, Denmark)	Yes, (Sørli et al., 2015b)	
"Footwear repel"	Granger's (Derbyshire, UK)		
"Performance repel"	Granger's (Derbyshire, UK)		

* full names "HG water, oil, fat & dirt proof for textile" and "HG water, oil, fat & dirt proof for leather" respectively.

Collection of respiratory parameters

The Notocord Hem (Notocord Systems SA, Croissy-sur-Seine, France) data acquisition software was used to collect and calculate several mouse respiratory parameters. We used the tidal volume (VT, mL) and respiratory frequency (breaths/min), but the program also calculates parameters linked to airway irritation and other parameters not reported in this study. Atelectasis may be observed as an irreversible decrease in VT, concurrent with a compensatory increase in respiratory frequency (Nørgaard et al., 2010, 2014). Comprehensive descriptions of the breathing parameters and their interpretation have been made elsewhere (Alarie, 1973; Vijayaraghavan et al., 1993; Larsen and Nielsen, 2000). Data acquisition and calculations were performed as described previously (Larsen et al., 2004).

Mouse bioassay for evaluation of acute inhalation toxicity

To assess the acute effects of IPs on respiration, groups of mice (n=4-10, see Tab. S1, doi:10.14573/altex.1705181s) were placed in individual, whole body plethysmographs and exposed head-out. First, a 15-min baseline period was recorded for each mouse while inhaling laboratory air. Then, the mice were exposed to the IP until the breathing pattern was affected, or for a maximum of 60 min. To assess exposure-related effects, the respiratory parameters during exposure were compared in real time to baseline levels, i.e., each mouse served as its own control. For each mouse, mean values of each minute during the experiment were calculated. Examples of concentration- and time- dependent effect curves can be found in (Nørgaard et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b)

For the products "Stain repellent", "Stain repellent nano" and "Antismuds" the No Observed Adverse Effect Concentration (NOAEC) was found by exposing a group of 8-10 mice to a high starting concentration, and then decreasing the concentration used

to expose other groups of mice until no effect was seen on the VT. For the IP “Liquid stain protection” groups of 8-10 mice were subjected to a high starting concentration, followed by lower concentrations, but the NOAEC was determined after doing a range-finding experiment, followed by a NOAEC experiment (see below). For the remaining seven IPs the following was done: an initial range-finding experiment was performed by exposing a group of mice (n=4-5) to increasing concentrations of IP. The start concentration was set based on data from the cf-CDS method, i.e., an IP that inhibited LS function started at a lower concentration than a product that did not inhibit LS *in vitro*. This was done to ensure that the first concentration would not cause acute inhalation toxicity. Following recording of the baseline, the start concentration was used during the first 15 minutes of exposure, and if no effect was observed at the previous concentration the infusion flowrate was then doubled every 15 min. If no effect was observed after a total of 60 min exposure (and testing of four concentrations), a second range-finding experiment was done using a new group of mice and the flow rate was increased until the highest concentration that could be generated in the system was reached. If no effect occurred during any of the range-finding experiments, a group of mice (n=5-7) was exposed to the highest concentration that could be generated and this concentration was designated the NOAEC. If, on the other hand, an effect occurred in the range-finding experiment, a group of mice (n=5-7) was subjected for 60 min to the concentration previous (lower) to the one causing the effect in the range-finding experiment. If no reduction in VT was observed during this experiment, this concentration was denoted the NOAEC. However, if an effect did occur during the 60 min period, the concentration was reduced again by half and this exposure concentration was generated for 60 min as described above.

Refinement of the in vivo model

We have worked with the acute airway effect of IPs for several years (Nørgaard et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b), and during this period, the *in vivo* bioassay has gone through several rounds of refinement.

From the first sets of experiments (Nørgaard et al., 2010, 2014), we know that the toxic response to IPs is very uniform, and manifests as a rapid reduction in VT. Animals with a toxic response to the IPs are in a moribund state and will die within 24 hours (Nørgaard et al., 2010), and the reduction of VT is irreversible and recovery does not occur (Nørgaard et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b). A severe reduction in VT during the experiment (>50% reduction compared to baseline) can lead to deaths during exposure (Nørgaard et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b). Based on these observations, we reduced the group size in each experiment from n=10 to n=4-5 during range-finding, and to n=5-7 for determination of the NOAEC. The animals were removed after the experiment and killed immediately by cervical dislocation without a period of recovery, to reduce the amount of time a single animal was exposed and restrained. In addition, animals with a rapid reduction in VT were removed from the exposure chamber and killed immediately. Finally, data from the cf-CDS method was used to determine the start concentration in the range-finding experiment, so that exposure to products inhibiting LS *in vitro* started at a lower concentration and accidental induction of acute inhalation effects were prevented.

Exposure monitoring

Exposure concentrations in the bioassay were calculated by gravimetric filter sampling (described in (Clausen et al., 2003)) combined with measurement of the non-volatile compounds of the products to calculate the wet weight of the product exposure. To determine the non-volatile fraction of the products, approximately 1 mL of test IP was transferred to a pre-weighed 2 mL glass vial and purged to dryness at ambient temperature by a gentle stream of nitrogen. The non-volatile fraction was determined gravimetrically in duplicate. Aerosol particle size distribution was measured for the 10 previously published bioassays (Nørgaard et al., 2010; Duch et al., 2014; Sørli et al., 2015b) (Tab. S2, doi:10.14573/altex.1705181s). These IPs contained a variety of solvents and active ingredients, and aerosolization consistently produced inhalable droplets. The same aerosolization technique was used in the present publication. We therefore assumed that the additional products tested for this publication also produced respirable droplets.

Human toxicity

Six of the tested products have accidentally been inhaled by and associated with toxicity in humans.

1-2) The product “HG leather” had been used in an unventilated room and a woman that had used the product felt like she was going to faint, but there were no respiratory complaints at the time of the emergency call. The product “HG textile” was involved in two poisoning cases. In the first case a woman complained of dyspnea, cough, dizziness, tiredness and myalgia the day after using the product. On examination, there were no signs of pneumonia or fever, and her oxygen saturation was normal. In the second case, a woman had sprayed two whole cans (2 x 300 ml) of the product and two days later complained of headache, dyspnea and cough. Upon examination, she did not have a fever and the oxygen saturation was 97%. Information on these three cases was provided by the Dutch poison center.

3) A worker sprayed 10-15 L of the product “Faceal Oleo MG” on a tile surface using a low-pressure spraying device, the application took approximately 30 min. The location, a staircase leading down to a metro station, was partly open to ambient air, but without active ventilation. The person did not wear respiratory protection during the application. The worker started coughing 20 minutes after the spraying, developed chills and was taken to hospital where he presented with slightly decreased O₂ saturation. The symptoms resolved after 24 h, but the patient subsequently developed non-allergic asthma.

4) The “Wood impregnation” product was involved in an inhalation toxicity accident involving 10 workers. One liter of the product was sprayed in a workshop, and one person that entered the workshop shortly after the application rapidly developed respiratory symptoms, and was diagnosed with severe chemical pneumonitis. Nine people, working in the room next door, were exposed 15 hours after the spraying incidence, experienced dry cough and chest tightness (Scheepers et al., 2016).

5) The “Liquid stain protection” product caused 11 described cases of intoxication between 2003 and 2011 related to application of the product. Symptoms ranged in severity from minor to severe, but all cases presented with initial severe cough (Hahn et al., 2015).

6) The product “Stain Repellent Super” was the cause of a large inhalation exposure accident in Greenland when the IP was sprayed on the ground floor of a supermarket, using an airless spray gun. In the hours following the application 43 people contacted the local hospital with respiratory symptoms, and thereof 39 were clinically examined. Their symptoms included coughing, tachypnoea, chest pain, general malaise and fever. The physical examination revealed perihilar lung infiltrates on chest radiographs and reduced blood oxygen saturation. The acute symptoms resolved gradually within 1–3 days and no delayed symptoms were observed. The incidents is described in detail in (Duch et al., 2014).

3 Results

3.1 Lung surfactant inhibition *in vitro*

21 IPs were tested in the cf-CDS method. Five IPs had no inhibitory effect, whereas 16 products inhibited LS function (Tab. 2).

3.2 *In vivo* toxicity in mice

The NOAEC of 10 of the IPs had been determined in the mouse bioassay previously (see Tab. 1), thus for this work, an additional 11 IPs were tested. NOAEC was determined *in vivo* and defined as the highest concentration at which there was no change in VT compared to baseline. Of the 21 products, 8 did not affect VT, even at the highest exposure concentration possible to generate (Tab. 2).

Tab. 2: Summary of the effect of impregnation products on LS function *in vitro*, on the breathing pattern of mice, correlation between *in vitro* and *in vivo* results, and involvement in human acute inhalation toxicity accidents

Impregnation product	<i>In vitro</i> LS inhibition	<i>In vivo</i> toxicity	Correlation <i>in vitro</i> - <i>in vivo</i>	Human toxicity
"Wood impregnation"	Yes	Yes	Yes	Yes
"Stain repellent super"	Yes	Yes	Yes	Yes
"Liquid stain protection"	Yes	Yes	Yes	Yes
"Facéal oleo MG"	Yes	Yes	Yes	Yes
"HG textile"	Yes	Yes	Yes	Yes
"HG leather "	Yes	Yes	Yes	Yes
"Antismuds"	Yes	Yes	Yes	-
"Footwear protector"	Yes	Yes	Yes	-
"Nakano impregnation"	Yes	Yes	Yes	-
"Non-absorbing floor materials"	Yes	Yes	Yes	-
"Rim sealer"	Yes	Yes	Yes	-
"Stain repellent nano"	Yes	Yes	Yes	-
"Stain repellent"	Yes	Yes	Yes	-
"Bath and tiles"	No	No	Yes	-
"Facéal oleo HD"	No	No	Yes	-
"Special textile coating"	No	No	Yes	-
"Textiles and leather concentrate"	No	No	Yes	-
"Textiles and leather"	No	No	Yes	-
"Car glass"	Yes	No	No, false positive	-
"Footwear repel"	Yes	No	No, false positive	-
"Performance repel"	Yes	No	No, false positive	-

3.3 Correlation of *in vitro*, *in vivo* and human data

The effect of IPs on LS function *in vitro* is summarized in Tab. 2, alongside their effects *in vivo* in mice and their involvement in human toxicity accidents, if any. Overall there is correlation between classification of a product as inhibitory or not *in vitro* and the presence or absence of toxicity to mice for 18 of the 21 IPs. Importantly, all 13 products that were toxic to mice also inhibited LS *in vitro*. Thus, the sensitivity (true positive rate) of the *in vitro* method is 100%. There were also no false negatives, i.e. no products were classified as “not inhibitory” to LS while toxic to mice. There were 8 products that were non-toxic to mice, but only 5 of these did not inhibit LS function *in vitro*, therefore the specificity (true negative rate) of the cf-CDS method was 5/8 = 63%. In other words, the false positive rate *in vitro*, i.e. the likelihood of labeling a product as toxic *in vitro* when it did not have an effect *in vivo*, is 37%. In humans, 6 of the 21 investigated IPs have given rise to cases of acute inhalation toxicity. All of these 6 products also caused *in vivo* toxicity in the mice and inhibition of LS *in vitro*.

4 Discussion

Impregnation products consist of very complex chemical mixtures. They contain active ingredients, which form a water and dirt repellent surface film after application, solvents that carry the active ingredient, and in some cases also a propellant. Each product may contain several different substances in each of these categories. The cause of the observed toxicity of IPs has been suggested to relate to the overall chemical composition of the products, rather than individual chemicals (Nørgaard et al., 2014). We and other researchers have not been able to identify a clear relationship between the content of specific groups of chemicals and the toxicity of IPs. As an example, fluorinated compounds are found both in toxic and non-toxic products (e.g., “Rim sealer” and “Textiles and

leather”, respectively, see Table S2, doi:10.14573/altex.1705181s). A strategy to make products safe has been to use water as a solvent, however, “Footwear protector” is toxic whereas “Performance repel” is not – though both are water-based (Tab. S2, doi:10.14573/altex.1705181s). To complicate matters further, it has previously been shown that different solvents modify the toxicity of an active ingredient – or may even be a prerequisite for its toxicity (Nørgaard et al., 2014). Thus, the toxicity of a particular IP is hard to predict, and several different chemical compositions can lead to a toxic response. The current knowledge does not allow prediction of inhalation toxicity of an IP based on its chemical composition. Safety testing of all possible combinations of substances by the conventional *in vivo* bioassay is not a rational option. Regulation of specific products is further hampered by a common lack of the name of the toxic product in case reports. Even when the product name is available it does not grant access to the complete chemical composition as Material Safety Data Sheets are often incomplete. Finding a good approximation of the acute and serious lung reaction will ease the identification of hazardous products, during product development and upon suspicion of toxicity of specific products.

IPs may cause acute inhalation toxicity to consumers and the effects of the inhalation are moderate to severe. In this paper, we describe a method that can be used to screen for toxicity of IPs. The method could detect all the products that were toxic to mice upon inhalation. Even more importantly, all products that have given rise to inhalation toxicity in humans, gave rise to adverse effects in the *in vitro* model. The method has proven useful for determining the toxicity of IPs, however we do not know if it can be used with the same success with other chemical classes. We will continue the work with other substances to determine if the method can be used to predict the inhalation toxicity of other inhaled substances. As part of developing the cf-CDS method we tested commercially available pharmaceutical formulations intended for inhalation (Sørli et al., 2015a). These formulations have proven to be safe for humans to inhale, and we found no effect on LS function, even at extreme concentrations. This and testing the method with IPs are the first steps in the process of making an alternative method for acute inhalation toxicity testing in animals (OECD TG 403 or 436, OECD, 2009a,b).

The cf-CDS method only screens for acute inhalation toxicity related to disruption of LS function. There may be other mechanisms associated with inhalation toxicity, which are not related to LS inhibition, such as cytotoxicity or systemic toxicity, these mechanisms will not be picked up by the LS inhibition method. This has to be taken into consideration before the assay can be accepted by regulators. An *in vitro* method that can measure cytotoxicity and systemic toxicity may be required before the current guidelines (OECD TG 403 or 436, OECD, 2009a,b) can be completely replaced. The cf-CDS method did not falsely identify acutely toxic products as safe, i.e. no false negative results were observed. The cf-CDS method did however identify some products as toxic even if no reaction were observed in the mouse bioassay (false positives). Curosurf®, the LS used in the *in vitro* tests, does not contain all the components found in natural lung surfactant, such as the proteins SP-A and SP-C and cholesterol. This difference may make the surfactant more sensitive to inhibition, and may be the reason for the false positives predicted by the *in vitro* method. However, even if natural surfactant may be a better approximation to lung function *in vivo*, it is difficult to obtain in sufficient and reliable amounts. An alternative method to the existing OECD guidelines using animals cannot rely on laborious collection of surfactant, when there are commercially, well characterized and controlled LS preparations readily available. We have therefore chosen to base the cf-CDS method on a commercial LS preparation.

We have previously shown that when IPs were tested in other *in vitro* models of LS inhibition (in the Langmuir trough or using the Capillary surfactometer), the results correlated well with inhalation toxicity in mice (Duch et al., 2014; Sørli et al., 2015b). However, neither method could mimic physiological relevant conditions, such as the frequency of cycling between the maximum and minimum surface area of the LS film, and manipulation of the atmosphere that the LS film was exposed to. One of the methods (the Capillary surfactometer (Sørli et al., 2015b)) was limited to the study of water soluble products. In contrast, the cf-CDS method is much more suitable for testing the interaction of chemicals with the LS, as the method mimics the physiological conditions of the lung, such as cycling frequency, the extent of the compression, and temperature. The cf-CDS method can test products of any composition, the exposure concentration can be continuously increased, and the exposure concentration can be monitored (Sørli et al., 2015a).

Of the 21 products tested, 13 were toxic to mice, and also inhibited the LS function *in vitro*. It is however not possible to use the *in vitro* ranking to predict the NOAEC exposure concentration *in vivo*. There are several reasons for this, but one important factor is the difference in exposure concentration measurement. For the mouse bioassay, the concentration is calculated by combining filter measurements of the exposure atmosphere and the dry weight of the non-volatile fraction after drying with a stream of N₂. For the cf-CDS method the concentration is calculated as the non-volatile fraction of the IP that settles on the QCM and has not evaporated after drying for 5 minutes under a stream of air. When an IP is dried; under a flow of nitrogen, during a flow of air in the animal exposure chamber, or in the CDS chamber, the drying is different; therefore, the measured exposure concentrations are not directly comparable. Instead the *in vitro* method can be used as a qualitative toxic/non-toxic screening method prior to or instead of the mouse bioassay. As we develop the cf-CDS method further we will try to make more comparable measurements of exposure concentration, e.g. by measuring the aerosol composition in both chambers.

The concentration of LS used in the *in vitro* assay (2.5 mg/ml) is lower than the concentration in the lung lining fluid. The surfactant concentration in the alveolar hypophase is estimated to range from 30 to 100 mg/mL, depending on the specific mammalian species (Zuo et al., 2008). However, we and others have found the same equilibrium, minimum and maximum surface tension of a range of surfactant concentrations (0.5 to 28 mg/ml), surfactant preparations (Infasurf, BLES and Curosurf®) and method of analysis (pulsating bubble surfactometer, captive bubble surfactometer or CDS) (Bachofen et al., 2005; Acosta et al., 2007; Zuo et al., 2008; Valle et al., 2014, 2015). If the existing guideline for measuring acute inhalation toxicity using animals is going to be replaced, the replacement has to be cheap and easy to perform. Using 2.5 mg/ml as the test concentration in the *in vitro* method is a good approximation to the lungs when measured according to the surface tension.

The relatively high false positive rate (the *in vitro* method predicted 37% of the non-toxic IPs as toxic) may be a drawback of the method. However, if these are still tested in animals there is a high risk of testing toxic products and causing suffering to the animals.

Based on the knowledge of the current project and earlier work (Sørli et al., 2015a), we would recommend that potential products first be tested *in vitro* and that the results from this test will determine the progression to animal testing. Products that inhibit LS function should be discarded or reformulated before a new *in vitro* test is performed. IPs that do not inhibit LS function will still need to be tested in animals. However, as the method is tested with more potentially inhaled substances, we believe that the cf-CDS, possibly in combination with other *in vitro* assays, will be able to completely replace the currently accepted acute inhalation toxicity test. Using this approach will reduce the suffering that would otherwise have occurred during testing of toxic products, and will reduce the number of animals needed for testing.

Six of the products tested have been involved in cases where up to 43 people were exposed to aerosols of the product and subsequently fell ill. Human acute inhalation toxicity often occurs when consumers do not use the product as intended by the producer, e.g., by spraying a product that should be applied with a mop or brush, or using a nozzle producing small droplets (case number 6 and 3, respectively). However, in some of the inhalation toxicity cases, the products were intended for spraying (e.g., case 1 and 2).

In summary, testing whether an impregnation product causes inhibition of lung surfactant *in vitro* is an excellent way of screening products before they are marketed and potentially can cause harm to humans. The cf-CDS method is a promising model for such screening.

References

- Acosta, E. J., Gitiafroz, R., Zuo, Y. Y. et al. (2007). Effect of humidity on lung surfactant films subjected to dynamic compression/expansion cycles. *Respir. Physiol Neurobiol* 155, 255-267. doi:10.1016/j.resp.2006.06.009
- Alarie, Y. (1973). Sensory irritation by airborne chemicals. *CRC Crit Rev. Toxicol* 2, 299-363. doi:10.3109/10408447309082020
- Bachofen, H., Gerber, U., Gehr, P. et al. (2005). Structures of pulmonary surfactant films adsorbed to an air-liquid interface in vitro. *Biochim Biophys Acta* 1720, 59-72. doi:10.1016/j.bbame.2005.11.007
- Bennett, D., Bargagli, E., Refini, R. M. et al. (2015). Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent. *Int. J. Occup. Med. Environ. Health* 28, 775-779. doi:10.13075/ijom.1896.00462
- Bonte, F., Rudolphus, A., Tan, K. Y. et al. (2003). Severe respiratory symptoms following the use of waterproofing sprays. *Ned. Tijdschr. Geneesk* 147, 1185-1188.
- Burkhardt, K. K., Britt, A., Petrini, G. et al. (1996). Pulmonary toxicity following exposure to an aerosolized leather protector. *J. Toxicol. Clin. Toxicol* 34, 21-24. doi:10.3109/15563659609020228
- CDC - Centers for Disease Control and Prevention (1993a). From the Centers for Disease Control and Prevention. Severe acute respiratory illness linked to use of shoe sprays-Colorado, November 1993. *JAMA* 270, 2915-2916.
- CDC (1993b). Acute respiratory illness linked to use of aerosol leather conditioner-Oregon, December 1992. *MMWR Morb. Mortal. Wkly. Rep* 41, 965-967.
- CDC (2006). Brief report: Respiratory illness associated with boot sealant products-five states, 2005-2006. *MMWR Morb. Mortal. Wkly. Rep* 55, 488-490.
- Christensen, K. J., Olsen, J. E. and Fogh, A. (1984). Acute poisoning caused by inhalation of an aerosol spray used for waterproofing. *Ugeskr. Laeger* 146, 274-275.
- Clausen, S. K., Bergqvist, M., Poulsen, L. K. et al. (2003). Development of sensitisation or tolerance following repeated OVA inhalation in Balb/cJ mice. Dose-dependency and modulation by the Al(OH)₃ adjuvant. *Toxicology* 184, 51-68. doi:10.1016/S0300-483X(02)00583-8
- Daubert, G. P., Spiller, H., Crouch, B. I. et al. (2009). Pulmonary toxicity following exposure to waterproofing grout sealer. *J. Med. Toxicol* 5, 125-129. doi:10.1007/BF03161222
- de Groot, R., de Vries, I. and Meulenbelt, J. (2004). Abstract 45. Sudden increase of acute respiratory illness after using a spr ay product to water proof clothing and shoes. The European XXIV Association of Poisons Centres and Clinical Toxicologists International Congress *J. Toxicol. Clin. Toxicol* 42, 443.
- Duch, P., Nørgaard, A. W., Hansen, J. S. et al. (2014). Pulmonary toxicity following exposure to a tile coating product containing alkylsiloxanes. A clinical and toxicological evaluation. *Clin. Toxicol. (Phila)* 52, 498-505. doi:10.3109/15563650.2014.915412
- Ebbehøj, N. E. and Bang, J. (2008). Respiratory symptoms after the use of a painting primer product spray. *Ugeskr. Laeger* 170, 3070.
- Enhorning, G. (2001). Pulmonary surfactant function studied with the pulsating bubble surfactometer (PBS) and the capillary surfactometer (CS). *Comp Biochem. Physiol A Mol. Integr. Physiol* 129, 221-226. doi:10.1016/S1095-6433(01)00318-X
- Epping, G., Van, B. J. and Van, D., V (2011). Toxic alveolitis after inhalation of a water repellent. *Int. J. Occup. Med. Environ. Health* 24, 409-413. doi:0.2478/s13382-011-0038-7
- EU - European Commission (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. doi:10.2787/400140
- Fagan, D. G., Forrest, J. B., Enhorning, G. et al. (1977). Acute pulmonary toxicity of a commercial fluorocarbon-lipid aerosol. *Histopathology* 1, 209-223. doi:10.1111/j.1365-2559.1977.tb01660.x
- Fukui, Y., Tanino, Y., Doshita, K. et al. (2011). Diffuse alveolar hemorrhage arising after use of a waterproofing spray. *Nihon Kokyuki. Gakkai Zasshi* 49, 360-364.
- Hahn, A., Fischer, M., Walter, D. et al. (2015). Abstract 181. Serious magic-nano-like lung oedemas caused by a liquid stain protection product: Using two new tests as a combined screening tool for aerosol products. XXXV International Congress of the European Association of Poisons Centres and Clinical Toxicologists. *Clinical Toxicology* 53, 318-318. doi:10.3109/15563650.2015.1024953

- Hashimoto, K., Arita, K., Kajihara, T. et al. (2009). Two cases of lung injury due to inhalation of waterproofing spray--with special reference to pulmonary function disorder. *Nihon Kokyuki. Gakkai Zasshi* 47, 367-371.
- Heinzer, R., Ribordy, V., Kuzoe, B. et al. (2004). Recurrence of acute respiratory failure following use of waterproofing sprays. *Thorax* 59, 541-542.
- Hubbs, A. F., Castranova, V., Ma, J. Y. et al. (1997). Acute lung injury induced by a commercial leather conditioner. *Toxicol. Appl. Pharmacol* 143, 37-46. doi:10.1006/taap.1996.8053
- Ishizaka, A., Matsuda, T., Albertine, K. H. et al. (2004). Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. *Am. J. Physiol Lung Cell Mol. Physiol* 286, L1088-L1094. doi:10.1152/ajplung.00420.2002
- Jacobsen, P., Klixbull, U. and Jensen, K. (1999). Lung damage after use of conditioner sprays for leather and textiles. *Ugeskr. Laeger* 161, 4030-4031.
- Kelly, K. J. and Ruffing, R. (1993). Acute eosinophilic pneumonia following intentional inhalation of Scotchguard. *Ann. Allergy* 71, 358-361.
- Khalid, I., Godfrey, A. M. and Ouellette, D. R. (2009). Chemical pneumonitis and subsequent reactive airways dysfunction syndrome after a single exposure to a household product: A case report. *J. Med. Case. Rep* 3, 112. doi:10.1186/1752-1947-3-112
- Kikuchi, R., Itoh, M., Uruma, T. et al. (2015). Diffuse alveolar hemorrhage after use of a fluoropolymer-based waterproofing spray. *Springerplus* 4, 270. doi:10.1186/s40064-015-1079-3
- Laliberte, M., Sanfacon, G. and Blais, R. (1995). Acute pulmonary toxicity linked to use of a leather protector. *Ann. Emerg. Med* 25, 841-844. doi:10.1016/S0196-0644(95)70217-2
- Larsen, S. T. and Nielsen, G. D. (2000). Effects of methacrolein on the respiratory tract in mice. *Toxicol. Lett* 114, 197-202. doi:10.1016/S0378-4274(99)00300-8
- Larsen, S. T., Hansen, J. S., Hammer, M. et al. (2004). Effects of mono-2-ethylhexyl phthalate on the respiratory tract in Balb/c mice. *Hum. Exp. Toxicol* 23, 537-545. doi:10.1191/0960327104ht486oa
- Lazor-Blanchet, C., Rusca, S., Vernez, D. et al. (2004). Acute pulmonary toxicity following occupational exposure to a floor stain protector in the building industry in Switzerland. *Int. Arch. Occup. Environ. Health* 77, 244-248. doi:10.1007/s00420-004-0505-6
- Malik, M. S. and Chappell, B. (2003). Acute respiratory syndrome associated with extreme Superpruf aerosol. *Anaesthesia* 58, 1037-1038. doi:10.1046/j.1365-2044.2003.03415_19.x
- Muller-Esch, G., Brunk, E., Djonlagic, H. et al. (1982). Pulmonary effect of inhaling leather-impregnation sprays *Dtsch. Med. Wochenschr* 107, 692-695. doi:10.1055/s-2008-1070004
- Nakazawa, A., Hagiwara, E., Harada, S. et al. (2014). Surgically proven desquamative interstitial pneumonia induced by waterproofing spray. *Intern. Med* 53, 2107-2110. doi:10.2169/internalmedicine.53.2282
- Nielsen, G. D., Larsen, S. T., Hougaard, K. S. et al. (2005). Mechanisms of acute inhalation effects of (+) and (-)-alpha-pinene in Balb/c mice. *Basic Clin. Pharmacol. Toxicol* 96, 420-428. doi:10.1111/j.1742-7843.2005.pto_04.x
- Nørgaard, A. W., Larsen, S. T., Hammer, M. et al. (2010). Lung damage in mice after inhalation of nanofilm spray products: The role of perfluorination and free hydroxyl groups. *Toxicol. Sci* 116, 216-224. doi:10.1093/toxsci/kfq094
- Nørgaard, A. W., Hansen, J. S., Sørli, J. B. et al. (2014). Pulmonary toxicity of perfluorinated silane-based nanofilm spray products: Solvent dependency. *Toxicol. Sci* 137, 179-188. doi:10.1093/toxsci/kft225
- OECD (2009a). Acute Inhalation Toxicity OECD guideline for the testing of chemicals No. 403. doi:10.1787/9789264070608-en
- OECD (2009b). Acute Inhalation Toxicity - Acute Toxic Class Method OECD guideline for testing of chemicals No. 436. doi:10.1787/9789264076037-en
- Okonek, S., Reinecke, H. J., Fabricius, W. et al. (1983). Poisoning with leather-impregnation sprays. A retrospective analysis of 224 cases of poisoning. *Dtsch. Med. Wochenschr* 108, 1863-1867. doi:10.1055/s-2008-1069840
- Ota, H., Koge, K., Tanaka, H. et al. (2000). Acute respiratory failure due to inhalation of aerosol water proof agent. *Nihon Kokyuki. Gakkai Zasshi* 38, 485-489.
- Pauluhn, J., Hahn, A. and Spielmann, H. (2008). Assessment of early acute lung injury in rats exposed to aerosols of consumer products: Attempt to disentangle the "Magic Nano" conundrum. *Inhal. Toxicol* 20, 1245-1262. doi:10.1080/08958370802220634
- Scheepers, P. T. J., Masen-Poos, L., Van Rooy, F. et al. (2016). P293 Pulmonary injury associated with a spray application of a water-based waterproofing product. *Occupational and Environmental Medicine* 73, A219-A220. doi:10.1136/oemed-2016-103951.608
- Schicht, R., Hartjen, A. and Sill, V. (1982). Alveolitis after inhalation of leather-impregnation spray. *Dtsch. Med. Wochenschr* 107, 688-691. doi:10.1055/s-2008-1070003
- Sørli, J. B., Da Silva, E., Backman, P. et al. (2015a). A proposed in vitro method to assess effects of inhaled particles on lung surfactant function. *Am. J. Respir. Cell Mol. Biol* 54, 306-311. doi:10.1165/rcmb.2015-0294MA
- Sørli, J. B., Hansen, J. S., Nørgaard, A. W. et al. (2015b). An in vitro method for predicting inhalation toxicity of impregnation spray products. *ALTEX* 32, 101-111. doi:10.1165/rcmb.2015-0294MA
- Saad, S. M. and Neumann, A. W. (2016). Axisymmetric drop shape analysis (ADSA): An outline. *Adv. Colloid Interface Sci* 238, 62-87. doi:10.1016/j.cis.2016.11.001
- Tashiro, K., Matsumoto, Y., Nishizuka, K. et al. (1998). Mechanism of acute lung injury caused by inhalation of fabric protector and the effect of surfactant replacement. *Intensive Care Med* 24, 55-60. doi:10.1007/s001340050515
- Testud, F., Gabrielle, L., Paquin, M. L. et al. (1998). Acute alveolitis after using a waterproofing aerosol: Apropos of 2 cases. *Rev. Med. Interne* 19, 262-264. doi:10.1016/S0248-8663(97)89328-9

- Thibaut, G., Wylomanski, J. L. and Laroche, D. (1983). Pulmonary intoxication by accidental inhalation of a household aerosol water repellent. *Toxicol. Eur. Res* 5, 81-84.
- Tizzard, Z. and Edwards, J. N. (2004). Letter to the Editor: Acute respiratory effects following use of waterproofing sprays: Some UK experience. *Thorax*. <http://thorax.bmj.com/content/59/6/541.2.responses>
- Valle, R. P., Huang, C. L., Loo, J. S. C. et al. (2014). Increasing hydrophobicity of nanoparticles intensifies lung surfactant film inhibition and particle retention. *Acs Sustainable Chemistry & Engineering* 2, 1574-1580. [doi:10.1021/sc500100b](https://doi.org/10.1021/sc500100b)
- Valle, R. P., Wu, T. and Zuo, Y. Y. (2015). Biophysical influence of airborne carbon nanomaterials on natural pulmonary surfactant. *ACS Nano* 9, 5413-5421. [doi:10.1021/acsnano.5b01181](https://doi.org/10.1021/acsnano.5b01181)
- Vernez, D., Bruzzi, R., Kupferschmidt, H. et al. (2006). Acute respiratory syndrome after inhalation of waterproofing sprays: A posteriori exposure-response assessment in 102 cases. *J. Occup. Environ. Hyg* 3, 250-261. [doi:10.1080/15459620600628845](https://doi.org/10.1080/15459620600628845)
- Vijayaraghavan, R., Schaper, M., Thompson, R. et al. (1993). Characteristic modifications of the breathing pattern of mice to evaluate the effects of airborne chemicals on the respiratory tract. *Arch. Toxicol* 67, 478-490. [doi:10.1007/BF01969919](https://doi.org/10.1007/BF01969919)
- Wallace, G. M. and Brown, P. H. (2005). Horse rug lung: Toxic pneumonitis due to fluorocarbon inhalation. *Occup. Environ. Med* 62, 414-416. [doi:10.1136/oem.2004.015784](https://doi.org/10.1136/oem.2004.015784)
- Weibrecht, K. W. and Rhyee, S. H. (2011). Acute respiratory distress associated with inhaled hydrocarbon. *Am. J. Ind. Med* 54, 911-914. [doi:10.1002/ajim.20989](https://doi.org/10.1002/ajim.20989)
- Wong, K. L. and Alarie, Y. (1982). A method for repeated evaluation of pulmonary performance in unanesthetized, unrestrained guinea pigs and its application to detect effects of sulfuric acid mist inhalation. *Toxicol. Appl. Pharmacol* 63, 72-90. [doi:10.1016/0041-008X\(82\)90028-X](https://doi.org/10.1016/0041-008X(82)90028-X)
- Woo, O. F., Healey, K. M., Sheppard, D. et al. (1983). Chest pain and hypoxemia from inhalation of a trichloroethane aerosol product. *J. Toxicol. Clin. Toxicol* 20, 333-341. [doi:10.3109/15563658308990600](https://doi.org/10.3109/15563658308990600)
- Yamashita, M. and Tanaka, J. (1995). Pulmonary collapse and pneumonia due to inhalation of a waterproofing aerosol in female cd-1 mice. *J. Toxicol. Clin. Toxicol* 33, 631-637. [doi:10.3109/15563659509010620](https://doi.org/10.3109/15563659509010620)
- Zuang, V., Desprez, B., Barroso, J. et al. (2015). EURL ECVAM status report on the development, validation and regulatory acceptance of alternative methods and approaches (2015). Report EUR 27474 EN. [doi:10.2788/62058](https://doi.org/10.2788/62058)
- Zuo, Y. Y., Ding, M., Bateni, A. et al. (2004). Improvement of interfacial tension measurement using a captive bubble in conjunction with axisymmetric drop shape analysis (ADSA). *Colloids and Surfaces A-Physicochemical and Engineering Aspects* 250, 233-246. [doi:10.1016/j.colsurfa.2004.04.081](https://doi.org/10.1016/j.colsurfa.2004.04.081)
- Zuo, Y. Y., Veldhuizen, R. A., Neumann, A. W. et al. (2008). Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. *Biochim. Biophys. Acta* 1778, 1947-1977. [doi:10.1016/j.bbamem.2008.03.021](https://doi.org/10.1016/j.bbamem.2008.03.021)

Acknowledgments

The project was funded by the Danish 3R center and the EU project SmartNanoTox (grant agreement No. 686098). Axel Hahn and Dorothee Walter are thanked for information on the product "Liquid stain protection", Toke Winter for information on "HG leather" and "HG textile" toxicity in humans, and Michael Gulbrandsen, Brian Hansen and Signe Hjortkjær Nielsen for technical assistance.

Conflict of interest

The authors declare that they have no conflicts of interest.

Correspondence to

Jorid Birkelund Sørli, PhD
Det Nationale Forskningscenter for Arbejdsmiljø
Lersø Parkallé 105
2100 København Ø
Phone: +45 39 16 52 25,
Fax: +45 39 16 52 01,
E mail: jbs@nrcwe.dk